| Product Unit Size | Cost | Quantity | Stock |
|---|
This compound is a cysteine-isothiocyanate conjugate that exhibits antioxidative, cytoprotective, nephroprotective, and chemopreventive activities. In vivo, this compound decreases lung tumor formation induced by benzo[a]pyrene and NNK. Additionally, this isothiocyanate (ITC) increases expression and activity of heme oxygenase 1 (HO-1) and decreases renal tissue apoptosis induced by cisplatin. Like other ITCs, this compound also acts as a phase II enzyme inducer.
| Cas No. | 137915-13-0 |
|---|---|
| Purity | ≥98% |
| Formula | C13H18N2O2S2 |
| Formula Wt. | 298.42 |
| IUPAC Name | (2R)-2-amino-3-(3-phenylpropylcarbamothioylsulfanyl)propanoic acid |
| Synonym | S-(N-(3-Phenylpropyl)(thiocarbamoyl))-cysteine |
| Melting Point | 202-205°C |
| Solubility | Soluble in DMSO (4 mg/mL), water. |
| Appearance | White solid |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Tayem Y, Green CJ, Motterlini R, et al. Isothiocyanate-cysteine conjugates protect renal tissue against cisplatin-induced apoptosis via induction of heme oxygenase-1. Pharmacol Res. 2014 Mar;81:1-9. PMID: 24434421.
Hecht SS, Upadhyaya P, Wang M, et al. Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis. 2002 Sep;23(9):1455-61. PMID: 12189187.